- Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death
- Extrapyramidal side effects (EPS) including tardive dyskinesia and dystonia may occur with antipsychotics
- Antipsychotics have been associated with an increased risk of venous thromboembolism, especially early in therapy
- Cases of sudden death, QT-prolongation, and Torsades de Pointes have been reported in patients receiving haloperidol. This risk is further increased with IV use and the use of drugs that prolong the QTc interval, bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT. Use with caution in patients with cardiovascular disease
- Neuroleptic Malignant Syndrome manifesting with hyperpyrexia, muscle rigidity, altered mental status and autonomic instability has been reported in association with administration of antipsychotic drugs
- Possible risk of seizures; may lower seizure threshold
- Avoid abrupt withdrawal. Abrupt withdrawal in patients on maintenance therapy has been associated with transient dyskinetic signs
- It may impair mental or physical abilities. Advise patients not to engage in activities requiring mental alertness like driving a car or operating heavy machinery
- Monitor ECG at baseline and periodically
- Monitor CBC frequently during initial therapy if pre-existing leukopenia or if drug-induced leukopenia/neutropenia history and K & Mg in critically ill patients
- Monitor ophthalmological examinations if prolonged therapy
Cautions: Use cautiously in
- Hepatic impairment
- Cardiovascular disease
- Congenital QT syndrome
- Concurrent QT prolonging agents
- Hypothyroidism
- Thyrotoxicosis
- Leukopenia
- Dementia (increased risk of mortality)
- Cerebrovascular disease
- CNS depressant use
- CNS tumors
- Prostatic hyperplasia
- Intestinal obstruction
- Seizure history or risk of seizures
- Debilitated patients (dose reduction recommended)
- Elderly patients (dose reduction recommended)
Pregnancy Category:C
Breastfeeding: Limited data indicates that maternal doses of haloperidol up to 10 mg/day produce low levels in milk and do not affect the breastfed infant. However, very limited long-term follow-up data is available to confirm this. Monitor the infant for developmental milestones, especially if other antipsychotics are used concurrently. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 July 2010). Manufacturer recommends that women receiving haloperidol should not breast feed.
US Trade Name(s)
US Availability
haloperidol lactate (generic)
haloperidol decanoate (generic)
- INJ: 50 mg/mL
- INJ: 100 mg/mL
Haldol (haloperidol lactate)
Haldol (haloperidol decanoate)
- INJ: 50 mg/mL
- INJ: 100 mg/mL
Canadian Trade Name(s)
Canadian Availability
haloperidol (generic)
haloperidol decanoate (generic)
- INJ: 50 mg/mL
- INJ: 100 mg/mL
UK Trade Name(s)
UK Availability
Haldol
- INJ: 5 mg/mL (1, 2 mL amp)
Haldol (haloperidol decanoate)
- INJ: 50 mg/mL (1 mL amp)
- INJ: 100 mg/mL (1 mL amp)
Australian Trade Name(s)
Australian Availability
Haldol (haloperidol decanoate)
- INJ: 50 mg/mL (1 mL amp)
- INJ: 50 mg/mL (3 mL amp)
Serenace
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Haloperidol Decanoate 100 MG/ML SOLN [Vial] (APP PHARMACEUTICAL)
1 ml = $50.99
2 ml = $92.97 - Haloperidol Decanoate 100 MG/ML SOLN [Vial] (APP PHARMACEUTICAL)
5 ml = $225.98
15 ml = $625.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
10 mg/day): Start 10-15 times the daily oral dose; if conversion >100 mg, give balance in 3-7 days. Max: 450 mg/month
